Related Experiment Video
Updated: Jun 19, 2026

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
New hope for Rasmussen encephalitis?
Barbara Schmalbach1, Nicolas Lang
1Neurology, Christian-Albrechts-University Kiel, and Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Schleswig Holstein 24105, Germany.
Abstract:
Rasmussen encephalitis (RE) is characterized by chronic inflammation of one cerebral hemisphere which causes intractable epileptic seizures and progressive neurological deficits. Since antiepileptic pharmacotherapy is often ineffective the traditional therapy for Rasmussen encephalitis is hemispherectomy in one of its modern variants which renders the patient seizure free but leads to a severe deficit. To escape this dilemma, immunomodulatory therapeutic approaches such as rituximab, a monoclonal anti-CD20 antibody, offer an alternative and bear promising therapeutic potentials in Rasmussen encephalitis.
More Related Videos
08:38Overcoming Unresponsiveness in Experimental Autoimmune Encephalomyelitis (EAE) Resistant Mouse Strains by Adoptive Transfer and Antigenic Challenge
Published on: April 9, 2012
05:44A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
Published on: December 9, 2022
Related Concept Videos
Rocky Mountain Spotted Fever
Encephalitis l: Introduction
Arboviral Encephalitis
Encephalitis ll: Pathophysiology
Respiratory Syncytial Virus Disease
Viral Meningitis